Sunho Biologics announces further delay of FY2025 results; trading in SUNHO BIO-B remains suspended

Bulletin Express04-27

Sunho Biologics, Inc. (SUNHO BIO-B) disclosed a new postponement in releasing its audited financial results for the year ended 31 December 2025. The company now concedes it will miss the previously targeted 30 April 2026 deadline because its auditor has not finished the outstanding work on the 2025 annual audit.

The continued delay also means the 2025 Annual Report will not be dispatched by the 30 April 2026 cut-off stipulated under Listing Rule 13.46(2)(a). Sunho Biologics said it will issue further announcements to update shareholders on both the audit status and the revised timetable for publishing the annual results and despatching the report.

Trading in SUNHO BIO-B shares has been suspended since 9:00 a.m. on 1 April 2026 and will remain halted until the 2025 results are released. The company advises shareholders and potential investors to exercise caution when dealing in its securities.

The board currently comprises two executive directors (Mr. Zhang Feng and Ms. Jiang Xiaoling), one non-executive director (Mr. Fan Rongkui) and three independent non-executive directors (Mr. Chan Heung Wing Anthony, Ms. Feng Lan and Mr. Shi Luwen).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125895803?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125895803","market":"us","top_or_hot":-1,"title":"Sunho Biologics announces further delay of FY2025 results; trading in SUNHO BIO-B remains suspended","media":"Bulletin Express","content":"<p>Sunho Biologics, Inc. (SUNHO BIO-B) disclosed a new postponement in releasing its audited financial results for the year ended 31 December 2025. The company now concedes it will miss the previously targeted 30 April 2026 deadline because its auditor has not finished the outstanding work on the 2025 annual audit.</p>\n<p>The continued delay also means the 2025 Annual Report will not be dispatched by the 30 April 2026 cut-off stipulated under Listing Rule 13.46(2)(a). Sunho Biologics said it will issue further announcements to update shareholders on both the audit status and the revised timetable for publishing the annual results and despatching the report.</p>\n<p>Trading in SUNHO BIO-B shares has been suspended since 9:00 a.m. on 1 April 2026 and will remain halted until the 2025 results are released. The company advises shareholders and potential investors to exercise caution when dealing in its securities.</p>\n<p>The board currently comprises two executive directors (Mr. Zhang Feng and Ms. Jiang Xiaoling), one non-executive director (Mr. Fan Rongkui) and three independent non-executive directors (Mr. Chan Heung Wing Anthony, Ms. Feng Lan and Mr. Shi Luwen).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunho Biologics announces further delay of FY2025 results; trading in SUNHO BIO-B remains suspended</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunho Biologics announces further delay of FY2025 results; trading in SUNHO BIO-B remains suspended\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-27 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sunho Biologics, Inc. (SUNHO BIO-B) disclosed a new postponement in releasing its audited financial results for the year ended 31 December 2025. The company now concedes it will miss the previously targeted 30 April 2026 deadline because its auditor has not finished the outstanding work on the 2025 annual audit.</p>\n<p>The continued delay also means the 2025 Annual Report will not be dispatched by the 30 April 2026 cut-off stipulated under Listing Rule 13.46(2)(a). Sunho Biologics said it will issue further announcements to update shareholders on both the audit status and the revised timetable for publishing the annual results and despatching the report.</p>\n<p>Trading in SUNHO BIO-B shares has been suspended since 9:00 a.m. on 1 April 2026 and will remain halted until the 2025 results are released. The company advises shareholders and potential investors to exercise caution when dealing in its securities.</p>\n<p>The board currently comprises two executive directors (Mr. Zhang Feng and Ms. Jiang Xiaoling), one non-executive director (Mr. Fan Rongkui) and three independent non-executive directors (Mr. Chan Heung Wing Anthony, Ms. Feng Lan and Mr. Shi Luwen).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02898","symbol_name":"盛禾生物-B","start_time":0,"source_url":"","article_id":"1125895803","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125895803","pubTimestamp":1777301108,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sunho Biologics, Inc. (SUNHO BIO-B) disclosed a new postponement in releasing its audited financial results for the year ended 31 December 2025. The company now concedes it will miss the previously...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02898":"盛禾生物-B"},"translate_title":"Sunho Biologics宣布进一步推迟2025财年业绩；SUNHO BIO-B的交易仍暂停","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02898":1},"content_text":"Sunho Biologics, Inc. (SUNHO BIO-B) disclosed a new postponement in releasing its audited financial results for the year ended 31 December 2025. The company now concedes it will miss the previously targeted 30 April 2026 deadline because its auditor has not finished the outstanding work on the 2025 annual audit.\nThe continued delay also means the 2025 Annual Report will not be dispatched by the 30 April 2026 cut-off stipulated under Listing Rule 13.46(2)(a). Sunho Biologics said it will issue further announcements to update shareholders on both the audit status and the revised timetable for publishing the annual results and despatching the report.\nTrading in SUNHO BIO-B shares has been suspended since 9:00 a.m. on 1 April 2026 and will remain halted until the 2025 results are released. The company advises shareholders and potential investors to exercise caution when dealing in its securities.\nThe board currently comprises two executive directors (Mr. Zhang Feng and Ms. Jiang Xiaoling), one non-executive director (Mr. Fan Rongkui) and three independent non-executive directors (Mr. Chan Heung Wing Anthony, Ms. Feng Lan and Mr. Shi Luwen).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125895803","isCrawlerRequest":true}